VYNE Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 1, 2024
YARW$15.48-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash Flows From Operating Activities: | ||
| Net loss | $(28,452) | $(23,210) |
| Adjustments required to reconcile net loss to net cash used inoperating activities: | ||
| Depreciation | — | 72 |
| Stock-based compensation | 3,305 | 4,297 |
| Loss from sale and disposal of fixed assets | — | 282 |
| Gain on the sale of the MST Franchise | — | (12,918) |
| Amortization of premium or discount on marketable securities | (255) | — |
| Unrealized gains on cash equivalents | 1 | — |
| Changes in operating assets and liabilities: | ||
| Decrease in inventory | — | 97 |
| Decrease in trade receivables, prepaid and other current assets and operating lease right of use asset | 405 | 11,210 |
| Decrease in trade payables, accrued expenses, employee related obligations, liability for employee severance benefits and other long-term liabilities | (559) | (8,681) |
| Increase (decrease) in operating lease liabilities | 214 | (349) |
| Net cash used in operating activities | (25,341) | (29,200) |
| Cash Flows From Investing Activities: | ||
| Proceeds from the sale of the MST Franchise | 5,000 | 15,667 |
| Purchases of marketable securities | (62,354) | — |
| Net cash (used in) provided by investing activities | (57,354) | 15,667 |
| Cash Flows From Financing Activities: | ||
| Proceeds related to the issuance of common shares and pre-funded warrants through private placement, net of issuance costs | 82,665 | — |
| Proceeds related to the issuance of common shares through at-the-market offerings, net of issuance costs | 156 | 1,470 |
| (Redemption) proceeds of convertible preferred stock | (360) | 211 |
| Withholdings from exercise of options and issuance of shares for stock-based compensation arrangements, net | (67) | (28) |
| Net cash provided by financing activities | 82,394 | 1,653 |
| Decrease in cash, cash equivalents and restricted cash | (301) | (11,880) |
| Cash, cash equivalents and restricted cash at beginning of the year | 30,975 | 42,855 |
| Cash, cash equivalents and restricted cash at end of the year | $30,674 | $30,975 |
| Cash and cash equivalents | 30,620 | 30,908 |
| Restricted cash | 54 | 67 |
| Total cash, cash equivalents and restricted cash | $30,674 | $30,975 |
F - 5
| Year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Supplementary information on investing and financing activities not involving cash flows: | ||
| Accretion of preferred stock | $149 | $— |
| Issuance of shares under employee share purchase plan | $48 | $37 |
| Cashless exercise of warrants | $132 | $— |
| Amount due from sale of MST Franchise | $— | $5,000 |
| Additions to operating lease right of use assets | $207 | $— |
| Additions to operating lease liabilities | $214 | $— |
| Supplemental disclosure of cash flow information: | ||
| Interest received | $1,139 | $446 |
F - 6
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.